Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model

Published:2018-12 Issue:6 Volume:28 Page:536-546
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:

Author:

Kenessey István,Kramer Zsófia,István Lilla,Cserepes Mihály T.,Garay Tamás,Hegedűs Balázs,Dobos Judit,Tímár József,Tóvári József

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference49 articles.

1. Melanoma epidemiology and trends;Garbe;Clin Dermatol,2009

2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

3. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation;Young;Future Oncol,2012

4. Vemurafenib: targeted inhibition of mutated BRAF for treatment of advanced melanoma and its potential in other malignancies;Sharma;Drugs,2012

5. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma;Girotti;Cancer Discov,2013

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody dependent cellular cytotoxicity-inducing anti-EGFR antibodies as effective therapeutic option for cutaneous melanoma resistant to BRAF inhibitors;Frontiers in Immunology;2024-03-06

2. Role and Function of Receptor Tyrosine Kinases in BRAF Mutant Cancers;Receptors;2024-03-04

3. Novel biomolecules in targeted cancer therapy: a new approach towards precision medicine;Medical Oncology;2023-10-07

4. Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFR ^WT , EGFR ^T790M , and EGFR ^L858R );Journal of Enzyme Inhibition and Medicinal Chemistry;2023-08-07

5. Kinetics of RTK activation determine ERK reactivation and resistance to dual BRAF/MEK inhibition in melanoma;Cell Reports;2023-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3